carbamates has been researched along with Thromboembolism, Venous in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood." | 1.62 | Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. ( Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guha, A | 1 |
| Jain, P | 1 |
| Fradley, MG | 1 |
| Lenihan, D | 1 |
| Gutierrez, JM | 1 |
| Jain, C | 1 |
| de Lima, M | 1 |
| Barnholtz-Sloan, JS | 1 |
| Oliveira, GH | 1 |
| Dowlati, A | 1 |
| Al-Kindi, S | 1 |
1 other study available for carbamates and Thromboembolism, Venous
| Article | Year |
|---|---|
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |